Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the Am...
10 April 2021 - 10:30PM
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
biopharmaceutical company developing precision T cell therapies to
treat solid tumors, today presented a patient case study from the
Company’s ongoing Phase I/IIa THETIS trial in metastatic or
recurrent melanoma at the American Association for Cancer Research
(AACR) Annual Meeting 2021. Through a comprehensive translational
research program, data from Patient T-05 offer insight into the in
vivo dynamics of clonal neoantigen T cells (cNeT) post-dosing and
the potential to develop a potency-based release assay.
“As we move through our Phase I/IIa THETIS and
CHIRON clinical programs in metastatic melanoma and advanced
non-small cell lung cancer, it is important to quantify and
characterize cNeT, the active component in our precision T cell
therapy, prior to and after cell infusion,” said Dr Sergio
Quezada, Chief Scientific Officer of
Achilles. “The data from this case study show a polyclonal
response and demonstrate our ability to establish product
specificity, polyclonal reactivities, monitor persistence and
expansion, as well as derive associations to efficacy. These are
important differentiators of our technology that provide a
mechanistic understanding of TIL therapy and potentially lend
themselves to a reproducible potency assay.”
In a case study from the ongoing THETIS trial, a
patient diagnosed with cutaneous melanoma received a three-cycle
combination of ipilimumab and nivolumab which was stopped due to
toxicity. In 2020, the patient had a recurrent lesion excised and
cNeT manufactured through the VELOSTM process. The specificity and
fitness of the cNeT were measured by flow cytometric analysis of
IFN-γ and TNF-α cytokines, markers of T cell activity. Up to 53% of
the T cells in the manufactured product were reactive to the
patient’s own clonal neoantigens following stimulation. cNeT can be
tracked after dosing by using peptides that incorporate
patient-specific clonal mutations from the tumor to stimulate cells
from the blood of the patient. By using ELISpot technology to
detect cNeT that produce cytokine in response to this stimulus, the
expansion and persistence of cNeT in circulation can be
calculated.
Details of the poster presentation:
Poster Title: Characterization of a novel
clonal neoantigen reactive T cell (cNeT) product through a
comprehensive translational research programPoster
Number: 1508Poster Session Category /
Title: Immunology / Adoptive Cell TherapyThe poster
and full session details can be found at www.aacr.org. The
poster is also available in the Events & Presentations section
of the Achilles website at
https://ir.achillestx.com/events-and-presentations.
About Achilles TherapeuticsAchilles is a
clinical-stage biopharmaceutical company developing precision T
cell therapies targeting clonal neoantigens: protein markers unique
to the individual that are expressed on the surface of every cancer
cell. The Company has two ongoing Phase I/IIa trials, the CHIRON
trial in patients with advanced non-small cell lung cancer (NSCLC)
and the THETIS trial in patients with recurrent or metastatic
melanoma. Achilles uses DNA sequencing data from each patient,
together with its proprietary PELEUS™ bioinformatics platform, to
identify clonal neoantigens specific to that patient, and then
develop precision T cell-based product candidates specifically
targeting those clonal neoantigens.
Forward-Looking StatementsThis press release
contains express or implied forward-looking statements that are
based on our management's belief and assumptions and on information
currently available to our management. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, these statements relate to future events or our future
operational or financial performance, and involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by these forward-looking statements. The forward-looking
statements in this press release represent our views as of the date
of this press release. We anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we have no current intention of doing so except to the
extent required by applicable law. You should therefore not rely on
these forward-looking statements as representing our views as of
any date subsequent to the date of this press release.
Lee M. Stern – VP, IR & External
Communications+1 (332) 373-2634l.stern@achillestx.com
Consilium Strategic CommunicationsMary-Jane
Elliott, Sukaina Virji, Melissa Gardiner+44 (0) 203 709
5000achillestx@consilium-comms.com
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Aug 2023 to Aug 2024